In the early 1990s, Wafik El-Deiry helped identify a gene that explained one of cancer biology’s most essential acts of restraint: how a damaged cell stops dividing.

The gene was p21, also known as WAF1. At the time, gene names were less ceremonious, and WAF1 carried a trace of his own name. The discovery helped clarify how the p53 tumor suppressor pathway responds to cellular stress, DNA damage, chemotherapy, and radiation, placing Dr. El-Deiry’s work within one of the central biological stories of modern oncology.

The discovery also helped give cancer biology a therapeutic vocabulary that remains active today. By showing that mammalian cell-cycle progression could be restrained through CDK inhibition, p21/WAF1 strengthened interest in pharmacologic CDK inhibitors, drugs that have since become important in breast cancer treatment and continue to be investigated across tumor types, including in El-Deiry Cancer Research Laboratory.

From that early work, Dr. El-Deiry’s career has stretched from basic cancer biology to translational therapeutics, clinical trials, and the global effort to make precision oncology more intelligent, collaborative, and accessible.